查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
创新的契约模式:特殊疾病及罕见疾病治疗药的打入市场策略的重新定义
市场调查报告书
商品编码
1741561

创新的契约模式:特殊疾病及罕见疾病治疗药的打入市场策略的重新定义

Innovative Contracting Models: Redefining Market Access Strategies for Specialty and Rare Disease Drugs
出版日期: | 出版商: FirstWord Group | 英文 | 商品交期: 最快1-2个工作天内

价格
简介目录

本报告深入探讨了创新合约在製药业的策略运用，全面分析了何时以及如何有效地利用创新合约来确保市场进入。报告深入分析了创新合约的现状，并重点介绍了在哪些条件下创新合约最可行、最有利。

您将更了解创新合约面临的课题和机遇，包括其在肿瘤学和基因疗法等高成本疗法中的应用。报告还探讨了预测分析和人工智慧在製定合约策略中的作用，并强调了成功实施所需的实际考虑因素。在行业专家的贡献下，本报告为製药专业人士提供了应对创新合约复杂性和优化市场进入策略的知识。

关键问题

  • 1.创新合约的主要发展和市场趋势是什么？
  • 2.企业如何判断创新合约何时是可行的市场进入选择？
  • 3.哪些标准能让专家有资格就创新合约提供见解？
  • 4.包括美国和欧洲在内的不同市场如何看待创新合约？
  • 5.创新合约面临哪些课题与机会？
  • 6.企业如何利用创新合约优化其市场进入策略？

主要企业

  • Bristol Myers Squibb
  • CSL Behring
  • Lyfegen
  • Novartis
  • Novartis Gene Therapies
  • Prescient
  • Roche
  • Verpora

部分列表参与专家

  • Verpora 创新承包副总裁，常驻英国，业务涵盖全球
  • Prescient 真实世界证物副总裁，常驻英国，业务遍及全球
  • 市场准入：2023 年美国前 30 家製药公司（以收入计算）

方法论

檔案报告是基于独立且简洁的分析，这些分析源自于专有产业研究以及对产业思想领袖的深入访谈。报告深入分析了製药企业高管需要了解的关键发展和市场趋势，以应对未来的机会和课题。每份报告的重点都基于对二手文献的回顾和已发现的知识差距。基于这些初步研究，我们创建了基于证据、专家指导的讨论指南，以确保调查能够解答最重要的问题。此外，我们制定了严格的筛选标准，以确保受访者拥有足够的经验、知识和资格就该主题发表意见。

我们的报告有何特别之处？

FirstWord Reports 是值得信赖的行业领导者，专注于製药业，为生物製药专业人士和决策者提供详尽且切实可行的洞察。我们深厚的行业知识使我们能够提供相关且有价值的洞察，帮助您掌握新兴趋势，有​​效应对复杂课题。凭藉广泛的研究以及来自顶尖专家和关键意见领袖 (KOL) 的独立、公正的见解，我们的报告能够提供您所需的准确性和可靠性。独家独家访谈和数据，以及持续的市场监测，让您全面了解市场动态。我们的报告涵盖 40 多个活跃的疾病领域，包含包括关键意见领袖洞察和定量医生调查在内的医生情报，以及行业专家对医疗事务、数位健康、销售与行销、市场准入等领域问题的看法，使您能够做出更明智的数据驱动决策，从而在快速变化的行业中保持竞争力。

简介目录

This report delves into the strategic use of innovative contracting within the pharmaceutical industry, offering a comprehensive analysis of when and how these contracts can be effectively utilised to secure market access. It provides insights into the current landscape of innovative contracting, highlighting the conditions under which these agreements are most viable and beneficial.

Gain an understanding of the challenges and opportunities associated with innovative contracts, including their application in high-cost treatments like oncology and gene therapies. The report also explores the role of predictive analytics and AI in shaping contracting strategies and addresses the practical considerations necessary for successful implementation. With contributions from industry experts, this report equips pharmaceutical professionals with the knowledge to navigate the complexities of innovative contracting and optimise their market access strategies.

Key Questions Answered:

  • 1. What are the significant developments and market trends in innovative contracting?
  • 2. How can companies identify when an innovative contract is a viable market access option?
  • 3. What criteria qualify experts to provide insights on innovative contracting?
  • 4. How do different markets, including Europe and the US, approach innovative contracting?
  • 5. What are the challenges and opportunities associated with innovative contracting?
  • 6. How can companies optimise their market access strategies using innovative contracts?

Key Companies:

  • Bristol Myers Squibb
  • CSL Behring
  • Lyfegen
  • Novartis
  • Novartis Gene Therapies
  • Prescient
  • Roche
  • Verpora

Partial List of Participating Experts:

  • Vice President, Innovative Contracting, Verpora, based in the UK but covering the globe
  • Vice President, Real World Evidence, Prescient, based in the UK but covering the globe
  • Market Access, at a top 30 pharmaceutical company by 2023 global sales, based in the US

Methodology:

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.